

Serum betaine is inversely associated with low lean mass mainly in men in a Chinese middle-aged and elderly community-dwelling population

Bi-xia Huang¹, Ying-ying Zhu², Xu-ying Tan¹, Qiu-ye Lan¹, Chun-lei Li¹, Yu-ming Chen^{2*} and Hui-lian Zhu^{1*}

¹School of Public Health, Faculty of Nutrition, Sun Yat-sen University, Guangzhou 510080, Guangdong Province, People's Republic of China

²Department of Medical Statistics & Epidemiology, School of Public Health, Sun Yat-sen University, Guangzhou 510080, Guangdong Province, People's Republic of China

(Submitted 6 January 2016 – Final revision received 6 March 2016 – Accepted 7 March 2016 – First published online 15 April 2016)

Abstract

Previous studies have demonstrated that betaine supplements increase lean body mass in livestock and improve muscle performance in human beings, but evidence for its effect on human lean mass is limited. Our study assessed the association of circulating betaine with lean mass and its composition in Chinese adults. A community-based study was conducted on 1996 Guangzhou residents (weight/mass: 1381/615) aged 50–75 years between 2008 and 2010. An interviewer-administered questionnaire was used to collect general baseline information. Fasting serum betaine was assessed using HPLC-MS. A total of 1590 participants completed the body composition analysis performed using dual-energy X-ray absorptiometry during a mean of 3·2 years of follow-up. After adjustment for age, regression analyses demonstrated a positive association of serum betaine with percentage of lean mass (LM%) of the entire body, trunk and limbs in men (all $P < 0\cdot05$) and LM% of the trunk in women ($P = 0\cdot016$). Each SD increase in serum betaine was associated with increases in LM% of 0·609 (whole body), 0·811 (trunk), 0·422 (limbs), 0·632 (arms) and 0·346 (legs) in men and 0·350 (trunk) in women. Multiple logistic regression analysis revealed that the prevalence of lower LM% decreased by 17% (whole body) and 14% (trunk) in women and 23% (whole body), 28% (trunk), 22% (arms) and 26% (percentage skeletal muscle index) in men with each SD increment in serum betaine. Elevated circulating betaine was associated with a higher LM% and lower prevalence of lower LM% in middle-aged and elderly Chinese adults, particularly men.

Key words: Serum betaine: Body composition: Lean mass: Sarcopenia

Sarcopenia is a progressive and generalised decline in muscle mass and function with age⁽¹⁾ that is associated with increased risks of frailty fractures and mortality^(2,3). The prevalence of sarcopenia ranges from 5 to 13% in 60–70-year-olds and rises to 11–50% in people over 80 years of age⁽⁴⁾. Loss of muscle mass is a characteristic of 'pre-sarcopenia', which is the early stage of sarcopenia that does not impact muscle strength or physical performance⁽⁵⁾. Muscle mass decreases at a median annual rate of 0·37% in women and 0·47% in men from young (18–45 years) to old age (>65 years)⁽⁶⁾. Notably, muscle mass exhibits a positive relationship with strength⁽⁷⁾ and physical performance⁽⁸⁾. Sarcopenia-related annual healthcare expenditure is estimated at \$18 billion in the USA alone⁽⁹⁾. Effective preventive and therapeutic measures for sarcopenia, such as nutritional intervention, have become a medical and societal challenge because of the disabling complications and healthcare costs.

Betaine (trimethylglycine) acts as a methyl donor in the transmethylation of homocysteine and as an organic osmolyte,

and it is abundant in spinach, beets and whole grains⁽¹⁰⁾. Betaine is commonly added to animal feeds to improve lean meat yield and quality in pigs and chickens^(11,12). Previous human studies have also indicated a potential ergogenic value of betaine on athletic performance in endurance- and strength-based exercises^(13,14). However, evidence of its effect on human lean mass (LM) is limited. Neither 10 d (2 g/d) nor 12 weeks (6 g/d) of betaine supplementation improved body composition or fat-free mass in thirty-four sedentary young male subjects or forty-two middle-aged subjects restricted from exercising^(15,16). In contrast, a randomised-controlled trial demonstrated that a prescribed resistance training programme supplemented with betaine (2·5 g/d for 6 weeks) significantly improved body composition in twenty-three young males by increasing LM and reducing fat mass compared with placebo⁽¹⁷⁾. Our previous study⁽¹⁸⁾ demonstrated that higher circulating betaine is associated with better body composition by decreasing the percentage of visceral fat mass in a Chinese population. However, to our knowledge, there are no reports of an

Abbreviations: DXA, dual-energy X-ray absorptiometry; LLM, low lean mass; LM, lean mass; LM%, percentage of lean mass; WC, waist circumference.

* **Corresponding author:** Professor Y.-m. Chen, fax +86 20 8733 0446, email chenym@mail.sysu.edu.cn; Professor H.-l. Zhu, fax +86 20 8733 0446, email zhuhl@mail.sysu.edu.cn

association between betaine and lean body mass in the elderly, who are at risk of sarcopenia.

The aim of this study was to investigate the association between serum betaine and lean body mass of the whole body, trunk and limbs including arms and legs in middle-aged and elderly adults in a large community-dwelling population.

Methods

Study population

Data for this analysis were collected from a community-based study, which was a cohort study investigating the determinants of cardio-metabolic outcomes and osteoporosis in Chinese adults⁽¹⁹⁾. A total of 3169 participants (50–75 years old) were recruited from July 2008 to June 2010. All participants resided in Guangzhou (South China) for at least 5 years. They were recruited through local advertisements or from referrals in the local community. Persons who were diagnosed with serious chronic diseases or were using weight-reducing aids were excluded. Trained interviewers conducted face-to-face interviews to collect information on socio-demographic characteristics, lifestyle and food consumption using structured questionnaires. A total of 1996 of the 3169 initial participants provided serum betaine baseline specimens, and 1590 completed the follow-up tests between April 2011 and January 2013 (after a mean of 3.2 years). General information, serum betaine from baseline, anthropometric measurements and dual-energy X-ray absorptiometry (DXA)-derived body composition from the follow-up tests were used for analysis in this study. The Ethics Committee of the School of Public Health at Sun Yat-sen University approved the study protocol. Written informed consent was obtained from all the participants at initial enrolment and follow-up.

Serum betaine

Fasting venous blood samples were collected at baseline. Serum was separated by centrifugation and stored at -80°C until analysis. Serum betaine was measured using HPLC-tandem MS as described previously^(18,20,21). In brief, 60 μl of either serum or standards was deproteinised using 100 μl acetonitrile containing 10 μM internal standards of d9-betaine, and the samples were centrifuged at 13 000 **g** for 10 min to precipitate the proteins. Supernatants were injected into spin columns and centrifuged at 3000 **g** for 2 min to filter and remove impurities. Supernatants were collected and analysed by HPLC-MS (Agilent 6400 Series Triple Quad LCMS). The CV for the between-run assays were 6.21%.

Body composition

Weight and height were measured at baseline and follow-up while the participants were barefoot and wearing light clothes; BMI (kg/m^2) was calculated. Waist circumference (WC) was measured twice, and the average value was used for subsequent analyses. LM was measured using DXA (Discovery W; Hologic Inc.) of whole-body scans. DXA results were

analysed using Hologic Discovery software version 3.2. DXA measurements included LM and percentage values of the whole body, trunk and limbs (including arms and legs). Bone mineral content was subtracted from the original fat-free LM to determine non-bone LM, under the assumption that all non-fat and non-bone tissue is skeletal muscle. Percentage skeletal muscle index (SMI%) was defined as limb LM (kg)/body weight (kg) $\times 100\%$ ⁽²²⁾. The *in vivo* reproducibility values of LM in twenty-seven participants after re-positioning were 2.6, 3.2, 4.3 and 4.0% for left arms, right arms, left legs and right legs, respectively.

Covariate assessments

An interviewer-administered questionnaire was used at baseline to ascertain the following information: socio-demographic characteristics (e.g. age, sex and occupation); lifestyle habits (e.g. consumption of tobacco, alcohol and tea); years since menopause (for women only); habitual dietary intake in the year before the interview; physical activities; and history of chronic diseases and use of medication. Participants who smoked at least 1 cigarette/d, drank alcohol once weekly for at least 6 months or drank tea at least twice weekly were defined as smokers, alcohol drinkers or tea drinkers, respectively. Menopause was defined as the natural cessation of menstrual periods for more than 12 months. Dietary intakes of energy and protein were assessed using a seventy-nine-item quantitative FFQ⁽²³⁾. Dietary intake of protein was adjusted by total energy content using the residual method proposed by Willet & Stampfer⁽²⁴⁾. Daily physical activity was estimated using a nineteen-item questionnaire⁽²⁵⁾, including daily occupation, leisure-time activity and household chores, and was evaluated using metabolic equivalent-h/d.

Statistical analysis

All data were analysed and reported by sex. LM was adjusted for body weight using the residual method⁽²⁴⁾, and the results were used in subsequent linear regression analyses. Descriptive characteristics of the participants are presented as tertiles of serum betaine. Continuous data are reported as mean values and standard deviations or as medians and interquartile ranges in cases of non-normal distribution. Frequencies and percentages are reported for categorical data. One-way ANOVA, Kruskal–Wallis tests or χ^2 tests were used according to the above-mentioned types of data to test for overall differences between tertiles. Regression analysis adjusted for age was used to examine the linear associations between serum betaine (in *Z* scores) and LM indices. We further conducted subgroup analyses stratified by low- or high-level medians according to physical activities, BMI, WC, energy intake or energy-adjusted protein intake. Interactions were estimated via multiplicative interaction terms in the multivariate models. The logistic regression analysis was performed to obtain OR and 95% CI of the presence of low lean mass (LLM) per sd of serum betaine. LLM were defined as the lowest quartile of percentage of lean mass (LM%) or SMI% of the whole body, trunk, limbs, arms or legs⁽²⁶⁾. All tests were two-sided, and a *P* value <0.05

was considered to be statistically significant. Statistical analyses were performed using SPSS version 19.0 (SPSS Inc.).

Results

Participant characteristics

Table 1 presents participant characteristics in serum betaine tertiles. In all, 69% of the 1590 subjects were women. Median ages and serum betaine levels in women and men were 56.0 and 61.8 years and 45.8 and 53.5 $\mu\text{mol/l}$, respectively. Participants with higher serum betaine levels exhibited lower weight, BMI, WC and total LM but a higher total lean:fat ratio in both sexes; higher percentage of total LM was seen in men (all $P < 0.05$).

Associations of serum betaine and indices of lean mass

Table 2 shows age-adjusted regression coefficients of the associations of serum betaine with weight-adjusted LM and LM%. Each SD increase in serum betaine (women: 17.2 $\mu\text{mol/l}$; men: 17.7 $\mu\text{mol/l}$) in men was associated with increases from 0.346 (legs) to 0.811 (trunk) of LM% (all $P < 0.05$) and 0.342 of SMI% ($P = 0.001$). Marginal significances were observed for the weight-adjusted LM of the total body, limbs and legs. The trunk exhibited the strongest association with betaine, followed by arms, and legs exhibited the weakest association. Almost no significant associations were observed in women, except at the trunk for LM% ($P = 0.016$).

Associations of serum betaine and percentage of lean mass by subgroup

We examined whether the favourable associations with LM% were modified by age, physical activity, BMI, WC, energy intake and protein intake as stratified by medians. Significant associations were observed in women with lower physical activities, higher age and higher BMI at the trunk (all $P < 0.05$). Associations of serum betaine and LM% tended to be more pronounced in men. However, no significant interactions were found (all $P_{\text{interactions}} > 0.05$) (Table 3).

OR of low lean mass for serum betaine

Logistic regression analyses in model 1 demonstrated that higher serum betaine levels were linearly associated with a lower risk of having lower LM% in the total body and trunk in women and in the total body, trunk and arms, as well as lower SMI%, in men (all $P < 0.05$) (Fig. 1). The OR of LLM for each SD increase in serum betaine in model 2 were 0.83 (95% CI 0.71, 0.95) (total body) and 0.86 (95% CI 0.74, 0.99) (trunk) in women and 0.77 (95% CI 0.62, 0.95) (total body), 0.72 (95% CI 0.58, 0.90) (trunk) and 0.78 (95% CI 0.63, 0.97) (arms) in men (all $P < 0.05$). Greater betaine was also associated with a lower risk of having lower SMI% mainly in men (OR 0.74; 95% CI 0.60, 0.92) (Fig. 1).

Discussion

This large community-based study of 50–75-year-old Chinese adults demonstrated that higher serum betaine correlated to greater levels of LM% and a lower risk of having lower LM% at all studied sites except for legs in men, and a lower risk of having lower LM% in the total body and trunk in women, after adjusting for a variety of covariates. To our knowledge, this is the first study to directly examine and report positive associations between blood betaine levels and LM in humans.

Serum betaine levels in Chinese adults

In this study population, the serum betaine concentrations were 46.1 (SD 17.2) and 53.4 (SD 17.7) $\mu\text{mol/l}$ in women and men, respectively, which was lower than that (65.4 $\mu\text{mol/l}$) of 631 normal Shanghai men (China) with mean age of 56 (SD 5) years⁽²⁷⁾, but higher than the value of 39.5 (SD 12.5) $\mu\text{mol/l}$ among 7045 Norwegians aged 47–74 years⁽²⁸⁾ and of 16.89 (5.12) $\mu\text{mol/l}$ in Californian pregnancies⁽²⁹⁾. The between-study heterogeneity in serum betaine might be due to varied dietary patterns with different intakes of betaine-rich foods in different populations. The variations in the measurements and the gene polymorphisms of betaine metabolic enzymes in different ethnic groups might also partly account for the between-study differences.

Betaine and lean body mass

Previous observational human studies have demonstrated that plasma or serum betaine is inversely associated with weight, BMI, WC and body fat⁽²⁸⁾. These are consistent with our present results, in which higher serum betaine was associated with significantly lower body weight, BMI and WC. However, the relationship between serum betaine and body LM is not well elucidated. Although weight-adjusted LM did not show a significant association with serum betaine except in limbs in men, the LM% in our study exhibited a positive relationship with serum betaine. This may indicate that betaine influences body mass by reducing the fat mass while maintaining the LM. Higher serum betaine levels were linearly associated with a lower risk of having LLM. These observations are indirectly supported by previously published human studies. Previous studies have demonstrated that circulating betaine levels were inversely related to the percentage of body fat in a health examination population⁽²⁸⁾ and dyslipidaemia patients⁽³⁰⁾, which may be consistent with betaine being positively associated with LM%. Betaine supplementation was also shown to increase LM gain in the whole body in pigs and ham⁽³¹⁾.

Several mechanisms for the beneficial effects of betaine on lean muscle are possible. (1) Betaine performs a methionine-sparing and homocysteine antidotal effect by transmethylation homocysteine to methionine. Betaine conserves methionine for protein synthesis. Excess homocysteine generates homocysteine thiolactone (HCTL), which inhibits insulin/insulin-like growth factor (IGF-1)-mediated mRNA expression and enzyme activity involved in protein synthesis⁽³²⁾. Betaine may increase muscle protein by reducing HCTL. (2) Betaine may stimulate

Table 1. Association between serum betaine and characteristics and lean mass indices in women and men (Mean values and standard deviations; medians and interquartile ranges (IQR); numbers and percentages)

	Women (n 1098)							Men (n 492)						
	Tertile 1		Tertile 2		Tertile 3		<i>P</i> _{overall}	Tertile 1		Tertile 2		Tertile 3		<i>P</i> _{overall}
	Mean	SD	Mean	SD	Mean	SD		Mean	SD	Mean	SD	Mean	SD	
Betaine (μmol/l)	28.1	8.5	45.7	3.4	64.5	12.0		34.3	9.1	53.3	4.1	72.5	10.4	
Age (years)	56.9	4.9	56.7	5.0	56.6	4.6	0.648	59.1	4.9	59.5	5.4	59.9	5.1	0.382
Height (cm)	154.9	5.4	155.5	5.8	154.9	5.0	0.226	166.4	5.7	166.2	5.6	165.2	5.3	0.103
Weight (kg)	57.2	8.4	57.2	8.7	55.2	8.6	0.001	67.7	8.7	66.1	9.4	64.4	8.8	0.005
BMI (kg/m ²)	23.8	3.3	23.6	3.3	23.0	3.2	0.001	24.4	2.7	23.9	3.0	23.6	2.8	0.031
WC (cm)	84.4	8.7	84.4	8.8	82.6	8.8	0.006	87.2	8.1	85.8	8.3	84.8	8.2	0.031
Total lean mass (kg)	34.2	4.0	34.5	4.4	33.3	4.1	0.001	47.1	5.1	46.4	5.6	45.5	5.1	0.031
Percentage of total lean mass	60.7	4.4	61.2	3.9	61.4	4.2	0.087	70.7	3.9	71.5	4.0	71.9	4.2	0.020
SMI%	25.3	2.3	25.6	2.0	27.0	2.4	0.259	30.8	2.4	31.3	2.4	31.4	2.6	0.053
Total lean:fat ratio							0.030							0.022
Median	1.7		1.7		1.7			2.7		2.8		2.9		
IQR	1.5, 1.9		1.5, 1.9		1.5, 2.0			2.4, 3.2		2.5, 3.4		2.5, 3.4		
Physical activity (MET)							0.218							0.373
Median	8.7		9.2		9.4			7.9		8.1		9.0		
IQR	5.9, 12.6		6.2, 13.1		6.5, 13.1			3.9, 12.6		5.1, 13.4		4.9, 12.7		
Energy intake (kJ/d)														0.111
Median	7212.8		7488.9		7508.6			8374.7		9046.2		8852.9		
IQR	6138.8, 8590.2		6308.2, 8618.2		6369.3, 8633.3			7297.7, 9845.8		7272.6, 10462.9		7329.1, 10387.2		
Energy intake (kcal/d)							0.195							0.111
Median	1723.9		1789.9		1794.6			2001.6		2162.1		2115.9		
IQR	1467.2, 2053.1		1507.7, 2059.8		1522.3, 2063.4			1744.2, 2353.2		1738.2, 2500.7		1751.7, 2482.6		
Protein intake (g/d)							0.128							0.315
Median	66.4		70.4		69.3			73.4		80.1		76.7		
IQR	53.9, 81.1		56.1, 82.9		55.7, 83.3			60.7, 92.7		64.6, 96.0		63.8, 91.2		
Years since menopause							0.678							–
Median	8.9		8.4		8.7			–		–		–		
IQR	5.4, 13.5		5.3, 12.9		5.5, 13.0			–		–		–		
Ex-/current smoker							0.367							0.929
<i>n</i>	0		1		2			85		82		82		
%	0.0		0.3		0.5			51.8		50.0		50.0		
Alcohol drinker							0.252							0.656
<i>n</i>	10		9		4			27		23		29		
%	2.7		2.5		1.1			16.5		14.0		17.7		
Tea drinker							0.713							0.143
<i>n</i>	160		159		150			125		110		112		
%	43.7		43.4		41.0			73.9		68.1		68.3		

WC, waist circumference; SMI%, percentage skeletal muscle index, defined as limb lean mass (kg)/body weight (kg) × 100%; MET, metabolic equivalent.

B.-x. Huang *et al.*

Table 2. Differences in lean mass indices per SD of serum betaine in women and men* (β -Coefficients with their standard errors)

	Women			Men		
	β	SE	P	β	SE	P
Weight-adjusted lean mass (kg)						
Total	0.021	0.056	0.706	0.173	0.095	0.070
Trunk	0.013	0.030	0.656	0.032	0.050	0.521
Limbs	-0.004	0.033	0.910	0.128	0.064	0.046
Arms	-0.012	0.011	0.248	0.029	0.020	0.146
Legs	0.009	0.026	0.746	0.099	0.051	0.052
Percentage of lean mass						
Total	0.231	0.126	0.068	0.609	0.179	0.001
Trunk	0.350	0.145	0.016	0.811	0.216	<0.001
Limbs	0.111	0.150	0.461	0.422	0.175	0.016
Arms	0.347	0.200	0.083	0.632	0.216	0.004
Legs	0.028	0.153	0.855	0.346	0.172	0.044
SMI%	0.087	0.066	0.187	0.342	0.109	0.002

SMI%, percentage skeletal muscle index.

* The model was adjusted for age.

growth hormone secretion and activate the IGF-1 pathway to promote muscle fibre differentiation^(33,34). (3) Betaine increases sarcoplasmic osmolality via the osmoregulated betaine/GABA transporter-1 (BTG-1), which leads to cellular swelling under conditions of metabolic and ionic stress. Cellular swelling is sensed by sarcolemma integrins that are coupled to G proteins, which initiates a series of cascades via mitogen-activated protein kinase activation that results in protein synthesis and proteolysis inhibition⁽³⁵⁾. Cellular swelling also promotes protein synthesis by enhancing amino acid uptake.

Betaine on body lean mass differences in sex

The present study found that high circulating betaine was a potential protective factor to improve or maintain LM and prevent LLM. However, the OR were significant for lower LM% in the limbs and arms in men but not in women, which was consistent with the linear regression results. This sex difference has not been directly proposed in previous human studies, but in a study by Konstantinova *et al.*⁽²⁸⁾ the authors demonstrated a stronger correlation between betaine and BMI, WC and percentage of body fat in men than in women. Previous animal studies have also demonstrated that betaine may be more effective in altering body composition in barrows than in gilts⁽³⁶⁾. The reason for this sex difference has not been clearly clarified, but the different functions of sex hormones may partially explain the sex differences. Testosterone, but not oestradiol, exerts an assimilation function and stimulates muscle protein synthesis. Serum betaine is higher in men than in women. These differences in sex may be explained by the transcriptional regulation of human phatidylethanolamine *N*-methyltransferase (*PEMT*), which is an oestrogen-responsive gene for the endogenous synthesis of choline. Most of the women in our study were postmenopausal, who exhibit a lower capacity for *de novo* biosynthesis of the choline moiety⁽³⁷⁾, which may ultimately influence the endogenous generation of betaine. Therefore, the less significant association in women may also be due to the lower levels of endogenous generation and the lower concentration of betaine in blood.

Betaine and body lean mass by subgroups

We found that the betaine-LM association tended to be more pronounced in subjects with higher levels of energy intake, BMI and WC, but the biological mechanisms are not clear. Animal studies have demonstrated that betaine influenced protein synthesis, reduced lipogenesis and promoted lipolysis, which might increase the LM%⁽³³⁾. Betaine supplementation significantly decreased the activity of lipogenic enzymes in the subcutaneous adipose tissue of pigs⁽³⁸⁾ and abdominal adipose tissue of broilers⁽¹²⁾. Betaine supplementation also increased the activity of hepatic carnitine palmitoyltransferase 1 and promoted fatty acid oxidation⁽³⁹⁾. These results suggest that there is more potential for betaine to decrease fat mass and increase the LM% in people with higher (*v.* lower) BMI and WC.

Strengths and limitations

There are several strengths to our study. First, the relatively large sample size allowed us to obtain precise results. Next, the use of DXA allowed us to more precisely determine LM measurements than bioelectrical impedance analysis or body measures. Very strong correlations were reported previously between DXA-derived total-body lean soft tissue mass and MRI-derived total-body muscle mass in adult men and women aged 18–88 years (R^2 0.96)⁽⁴⁰⁾ and older women with a mean age of 71 years (r 0.94)⁽⁴¹⁾. Serum betaine was also used to assess internal exposure, which was more accurate and precise than dietary surveys alone, as the total betaine included exogenous food sources, and endogenous generation was also considered. Some limitations must be acknowledged as well. As extensively discussed in our previous article⁽¹⁸⁾, our study used a cross-sectional study design and betaine sample collection and DXA measurements occurred 3 years apart. We could not address whether there was a causal relationship between betaine and LM in our study. Another defect is that we had little information on muscle function in this population. We could not infer the relationship between serum betaine and muscle

Table 3. Sex-specific differences in percentage of lean mass indices per SD of serum betaine stratified by sarcopenia risk factors (β -Coefficients with their standard errors)

	Women									Men									
	Total			Trunk			Limbs			Total			Trunk			Limbs			
	β	SE	P	β	SE	P	β	SE	P	β	SE	P	β	SE	P	β	SE	P	
Physical activities (MET)																			
≤9.1*/8.3†	0.28	0.18	0.12	0.44	0.21	0.04	0.11	0.22	0.61	0.44	0.24	0.07	0.62	0.28	0.03	0.23	0.24	0.34	
>9.1*/8.3†	0.20	0.18	0.26	0.30	0.20	0.14	0.09	0.21	0.66	0.60	0.27	0.03	0.81	0.33	0.02	0.44	0.26	0.09	
<i>P</i> _{interaction}	0.737			0.622			0.952			0.646			0.666			0.553			
BMI (kg/m ²)																			
≤23.3*/23.9†	-0.11	0.16	0.49	-0.01	0.19	0.95	-0.24	0.20	0.21	0.33	0.24	0.18	0.43	0.30	0.15	0.25	0.24	0.29	
>23.3*/23.9†	0.26	0.14	0.07	0.37	0.15	0.01	0.16	0.20	0.41	0.32	0.20	0.10	0.51	0.22	0.02	0.10	0.22	0.63	
<i>P</i> _{interaction}	0.081			0.119			0.141			0.990			0.835			0.646			
WC																			
≤83.7*/85.8†	0.05	0.17	0.78	0.11	0.20	0.58	-0.04	0.20	0.83	0.24	0.22	0.29	0.32	0.28	0.25	0.18	0.22	0.43	
>83.7*/85.8†	0.12	0.15	0.40	0.25	0.15	0.10	0.01	0.20	0.94	0.49	0.21	0.02	0.73	0.24	0.002	0.25	0.23	0.29	
<i>P</i> _{interaction}	0.729			0.570			0.918			0.405			0.261			0.833			
Energy intake																			
≤1775.0*/2065.5†	0.28	0.18	0.12	0.41	0.21	0.06	0.15	0.21	0.49	0.23	0.26	0.37	0.32	0.31	0.30	0.19	0.26	0.45	
>1775.0*/2065.5†	0.22	0.18	0.21	0.36	0.20	0.07	0.07	0.21	0.73	0.83	0.26	0.001	1.13	0.31	<0.001	0.50	0.25	0.05	
<i>P</i> _{interaction}	0.801			0.866			0.801			0.103			0.066			0.388			
Protein intake																			
≤66.2*/74.6†	0.27	0.17	0.12	0.36	0.19	0.07	0.18	0.20	0.38	0.89	0.26	0.001	1.15	0.32	<0.001	0.67	0.25	0.01	
>66.2*/74.6†	0.24	0.19	0.21	0.42	0.22	0.06	0.04	0.23	0.87	0.22	0.25	0.38	0.36	0.30	0.23	0.06	0.25	0.81	
<i>P</i> _{interaction}	0.914			0.851			0.643			0.069			0.074			0.088			
Age (years)																			
≤56.0*/61.8†	0.19	0.18	0.27	0.32	0.22	0.14	0.06	0.20	0.77	0.72	0.22	0.001	0.95	0.27	0.001	0.48	0.22	0.03	
>56.0*/61.8†	0.30	0.18	0.10	0.44	0.20	0.03	0.17	0.23	0.46	0.37	0.31	0.23	0.51	0.36	0.16	0.27	0.31	0.39	
<i>P</i> _{interaction}	0.861			0.678			0.719			0.357			0.331			0.563			

MET, metabolic equivalent, WC, waist circumference.
 * Median for women.
 † Median for men.

	Model 1			Model 2		
	OR	95% CI	P	OR	95% CI	P
Women						
Total	0.83	0.72, 0.96	0.011	0.83	0.71, 0.95	0.010
Trunk	0.86	0.75, 0.99	0.039	0.86	0.74, 0.99	0.034
Limbs	0.95	0.83, 1.09	0.492	0.95	0.82, 1.09	0.459
Arms	0.92	0.80, 1.06	0.241	0.92	0.79, 1.05	0.220
Legs	0.98	0.85, 1.12	0.716	0.97	0.85, 1.12	0.703
SMI%	0.92	0.80, 1.06	0.255	0.93	0.80, 1.07	0.285
Men						
Total	0.77	0.63, 0.96	0.017	0.77	0.62, 0.95	0.016
Trunk	0.73	0.59, 0.90	0.003	0.72	0.58, 0.90	0.003
Limbs	0.82	0.67, 1.01	0.066	0.82	0.67, 1.02	0.070
Arms	0.77	0.63, 0.96	0.018	0.78	0.63, 0.97	0.026
Legs	0.84	0.68, 1.03	0.093	0.84	0.68, 1.03	0.093
SMI%	0.76	0.61, 0.94	0.011	0.74	0.60, 0.92	0.007

Fig. 1. Sex-specific OR and 95% CI of low lean mass per sd of serum betaine. Lower lean mass was defined as the lowest quartile of percentage of lean mass or percentage skeletal muscle index (SMI%). Model 1: adjusted for age. Model 2: model 1 further adjusted for energy intake, energy-adjusted protein intake, physical activity, alcohol consumption, smoking status, tea intake, years since menopause (women only).

strength or performance. DXA also cannot distinguish water retention or fat tissue infiltration within muscle, which may slightly overestimate muscle thickness. Kim *et al.*⁽⁴²⁾ estimated that fatty infiltration of muscle inflated skeletal muscle mass estimates from DXA by 1–8%.

Conclusions

Higher serum betaine is associated with increased LM% and a lower risk of LLM mainly in men. The finding that serum betaine related to decreased fat mass and improved or nearly unchanged LM suggested a beneficial effect on obesity-related sarcopenia. Further studies, particularly interventional studies, are needed to clarify whether there is a causative relationship between betaine and LM in humans.

Acknowledgements

The authors thank the numerous individuals who participated in this study.

This study was jointly supported by the National Science Foundation of China (nos 81273050 and 81472966) and the 5010 Program for Clinical Researches by Sun Yat-sen University, Guangzhou, China (no. 2007032). The funding sources had no role in the design, analysis or writing of this article.

H.-l. Z. and Y.-m. C. designed the study; Q.-y. L., C.-l. L., X.-y. T. and Y.-y. Z. conducted the study; B.-x. H. and Y.-m. C. analysed the data; H.-l. Z. and B.-x. H. wrote the paper. H.-l. Z. had primary responsibility for the final content. All the authors read and approved the final version of the manuscript.

There are no conflicts of interest.

References

1. Schwartz RS (1997) Sarcopenia and physical performance in old age: introduction. *Muscle Nerve Suppl* **5**, S10–S12.

2. Bortz WM 2nd (2002) A conceptual framework of frailty: a review. *J Gerontol A Biol Sci Med Sci* **57**, M283–M288.

3. Wannamethee SG, Shaper AG, Lennon L, *et al.* (2007) Decreased muscle mass and increased central adiposity are independently related to mortality in older men. *Am J Clin Nutr* **86**, 1339–1346.

4. Morley JE (2008) Sarcopenia: diagnosis and treatment. *J Nutr Health Aging* **12**, 452–456.

5. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, *et al.* (2010) Sarcopenia: European consensus on definition and diagnosis: report of the European Working Group on Sarcopenia in Older People. *Age Ageing* **39**, 412–423.

6. Mitchell WK, Williams J, Atherton P, *et al.* (2012) Sarcopenia, dynapenia, and the impact of advancing age on human skeletal muscle size and strength: a quantitative review. *Front Physiol* **3**, 260.

7. Newman AB, Haggerty CL, Goodpaster B, *et al.* (2003) Strength and muscle quality in a well-functioning cohort of older adults: the Health, Aging and Body Composition Study. *J Am Geriatr Soc* **51**, 323–330.

8. Buchner DM, Larson EB, Wagner EH, *et al.* (1996) Evidence for a non-linear relationship between leg strength and gait speed. *Age Ageing* **25**, 386–391.

9. Beaudart C, Rizzoli R, Bruyere O, *et al.* (2014) Sarcopenia: burden and challenges for public health. *Arch Public Health* **72**, 45.

10. Craig SA (2004) Betaine in human nutrition. *Am J Clin Nutr* **80**, 539–549.

11. Rojas-Cano ML, Lara L, Lachica M, *et al.* (2011) Influence of betaine and conjugated linoleic acid on development of carcass cuts of Iberian pigs growing from 20 to 50 kg body weight. *Meat Sci* **88**, 525–530.

12. Xing J, Kang L & Jiang Y (2011) Effect of dietary betaine supplementation on lipogenesis gene expression and CpG methylation of lipoprotein lipase gene in broilers. *Mol Biol Rep* **38**, 1975–1981.

13. Trepanowski JF, Farney TM, McCarthy CG, *et al.* (2011) The effects of chronic betaine supplementation on exercise performance, skeletal muscle oxygen saturation and associated biochemical parameters in resistance trained men. *J Strength Cond Res* **25**, 3461–3471.

14. Pryor JL, Craig SA & Swensen T (2012) Effect of betaine supplementation on cycling sprint performance. *J Int Soc Sports Nutr* **9**, 12.

15. del Favero S, Roschel H, Artioli G, *et al.* (2012) Creatine but not betaine supplementation increases muscle phosphorylcreatine content and strength performance. *Amino Acids* **42**, 2299–2305.

16. Schwab U, Torronen A, Toppinen L, *et al.* (2002) Betaine supplementation decreases plasma homocysteine concentrations but does not affect body weight, body composition, or resting energy expenditure in human subjects. *Am J Clin Nutr* **76**, 961–967.

17. Cholewa JM, Wyszczelska-Rokiel M, Glowacki R, *et al.* (2013) Effects of betaine on body composition, performance, and homocysteine thiolactone. *J Int Soc Sports Nutr* **10**, 39.

18. Chen YM, Liu Y, Liu YH, *et al.* (2015) Higher serum concentrations of betaine rather than choline is associated with better profiles of DXA-derived body fat and fat distribution in Chinese adults. *Int J Obes (Lond)* **39**, 465–471.

19. Liu YH, Xu Y, Wen YB, *et al.* (2013) Association of weight-adjusted body fat and fat distribution with bone mineral density in middle-aged Chinese adults: a cross-sectional study. *PLOS ONE* **8**, e63339.

20. Holm PI, Ueland PM, Kvalheim G, *et al.* (2003) Determination of choline, betaine, and dimethylglycine in plasma by a

- high-throughput method based on normal-phase chromatography-tandem mass spectrometry. *Clin Chem* **49**, 286–294.
21. Wang LJ, Zhang HW, Zhou JY, *et al.* (2014) Betaine attenuates hepatic steatosis by reducing methylation of the MTP promoter and elevating genomic methylation in mice fed a high-fat diet. *J Nutr Biochem* **25**, 329–336.
 22. Hong HC, Hwang SY, Choi HY, *et al.* (2014) Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study. *Hepatology* **59**, 1772–1778.
 23. Zhang CX & Ho SC (2009) Validity and reproducibility of a food frequency questionnaire among Chinese women in Guangdong province. *Asia Pac J Clin Nutr* **18**, 240–250.
 24. Willett W & Stampfer MJ (1986) Total energy intake: implications for epidemiologic analyses. *Am J Epidemiol* **124**, 17–27.
 25. Ainsworth BE, Haskell WL, Herrmann SD, *et al.* (2011) 2011 Compendium of Physical Activities: a second update of codes and MET values. *Med Sci Sports Exerc* **43**, 1575–1581.
 26. Rolland Y, Czerwinski S, Abellan Van Kan G, *et al.* (2008) Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives. *J Nutr Health Aging* **12**, 433–450.
 27. Butler LM, Arning E, Wang R, *et al.* (2013) Prediagnostic levels of serum one-carbon metabolites and risk of hepatocellular carcinoma. *Cancer Epidemiol Biomarkers Prev* **22**, 1884–1893.
 28. Konstantinova SV, Tell GS, Vollset SE, *et al.* (2008) Divergent associations of plasma choline and betaine with components of metabolic syndrome in middle age and elderly men and women. *J Nutr* **138**, 914–920.
 29. Shaw GM, Yang W, Carmichael SL, *et al.* (2014) One-carbon metabolite levels in mid-pregnancy and risks of conotruncal heart defects. *Birth Defects Res A Clin Mol Teratol* **100**, 107–115.
 30. Lever M, George PM, Dellow WJ, *et al.* (2005) Homocysteine, glycine betaine, and N,N-dimethylglycine in patients attending a lipid clinic. *Metabolism* **54**, 1–14.
 31. Matthews J, Southern L, Higbie A, *et al.* (2001) Effects of betaine on growth, carcass characteristics, pork quality, and plasma metabolites of finishing pigs. *J Anim Sci* **79**, 722–728.
 32. Najib S & Sanchez-Margalet V (2005) Homocysteine thio-lactone inhibits insulin-stimulated DNA and protein synthesis: possible role of mitogen-activated protein kinase (MAPK), glycogen synthase kinase-3 (GSK-3) and p70 S6K phosphorylation. *J Mol Endocrinol* **34**, 119–126.
 33. Cholewa JM, Guimaraes-Ferreira L & Zanchi NE (2014) Effects of betaine on performance and body composition: a review of recent findings and potential mechanisms. *Amino Acids* **46**, 1785–1793.
 34. Senesi P, Luzi L, Montesano A, *et al.* (2013) Betaine supplement enhances skeletal muscle differentiation in murine myoblasts via IGF-1 signaling activation. *J Transl Med* **11**, 174.
 35. Haussinger D (1996) The role of cellular hydration in the regulation of cell function. *Biochem J* **313**, 697–710.
 36. Lawrence B, Schinckel A, Adeola O, *et al.* (2002) Impact of betaine on pig finishing performance and carcass composition. *J Anim Sci* **80**, 475–482.
 37. Fischer LM, daCosta KA, Kwock L, *et al.* (2007) Sex and menopausal status influence human dietary requirements for the nutrient choline. *Am J Clin Nutr* **85**, 1275–1285.
 38. Huang Q, Xu Z, Han X, *et al.* (2008) Effect of dietary betaine supplementation on lipogenic enzyme activities and fatty acid synthase mRNA expression in finishing pigs. *Anim Feed Sci Technol* **140**, 365–375.
 39. Xu L, Huang D, Hu Q, *et al.* (2015) Betaine alleviates hepatic lipid accumulation via enhancing hepatic lipid export and fatty acid oxidation in rats fed with a high-fat diet. *Br J Nutr* **113**, 1835–1843.
 40. Kim J, Wang Z, Heymsfield SB, *et al.* (2002) Total-body skeletal muscle mass: estimation by a new dual-energy X-ray absorptiometry method. *Am J Clin Nutr* **76**, 378–383.
 41. Chen Z, Wang Z, Lohman T, *et al.* (2007) Dual-energy X-ray absorptiometry is a valid tool for assessing skeletal muscle mass in older women. *J Nutr* **137**, 2775–2780.
 42. Kim J, Heshka S, Gallagher D, *et al.* (2004) Intermuscular adipose tissue-free skeletal muscle mass: estimation by dual-energy X-ray absorptiometry in adults. *J Appl Physiol* **97**, 655–660.